{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T13:04:40Z","timestamp":1785416680696,"version":"3.56.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jtct.2026.04.035","type":"journal-article","created":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T14:49:48Z","timestamp":1777214988000},"page":"964.e1-964.e15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Outcomes of Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide Prophylaxis in Myelodysplastic Syndromes: A Multicenter Study Conducted on Behalf of GETH-TC"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4567-3682","authenticated-orcid":false,"given":"Mar\u00eda Queralt","family":"Salas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Jim\u00e9nez-Vicente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Chorao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Luque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Esquirol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estefan\u00eda P\u00e9rez","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7474-143X","authenticated-orcid":false,"given":"Marina Acera","family":"G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Gonz\u00e1lez Pinedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7372-5219","authenticated-orcid":false,"given":"Adolfo J.","family":"S\u00e1ez Mar\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Pe\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Pilar","family":"Gonz\u00e1lez-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inmaculada","family":"Heras Fernando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9622-1649","authenticated-orcid":false,"given":"Mar","family":"Torno D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4761-6692","authenticated-orcid":false,"given":"Sara","family":"Villar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00eda","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Filaferro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascual","family":"Balsalobre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Jes\u00fas","family":"Pascual Casc\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"D\u00edaz-Bey\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"26","key":"10.1016\/j.jtct.2026.04.035_bib0001","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1182\/blood.2023020079","article-title":"Clinical decision-making and treatment of myelodysplastic syndromes","volume":"142","author":"Hellstrom-Lindberg","year":"2023","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.jtct.2026.04.035_bib0002","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/s41409-025-02701-3","article-title":"Indications for haematopoietic cell transplantation and CAR-T for haematological diseases, solid tumours and immune disorders: 2025 EBMT practice recommendations","volume":"60","author":"Greco","year":"2025","journal-title":"Bone Marrow Transplant"},{"issue":"Suppl 4","key":"10.1016\/j.jtct.2026.04.035_bib0003","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/ajh.27660","article-title":"Allogeneic stem cell transplant for myelofibrosis and myelodysplastic syndromes: a contemporary review","volume":"100","author":"Gagelmann","year":"2025","journal-title":"Am J Hematol"},{"issue":"8","key":"10.1016\/j.jtct.2026.04.035_bib0004","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1002\/ajh.26984","article-title":"Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management","volume":"98","author":"Garcia-Manero","year":"2023","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.jtct.2026.04.035_bib0005","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/s41409-025-02524-2","article-title":"The 2023 EBMT report on hematopoietic cell transplantation and cellular therapies. Increased use of allogeneic HCT for myeloid malignancies and of CAR-T at the expense of autologous HCT","volume":"60","author":"Passweg","year":"2025","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.jtct.2026.04.035_bib0006","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/S2352-3026(23)00342-3","article-title":"Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation","volume":"11","author":"Penack","year":"2024","journal-title":"Lancet Haematol"},{"issue":"6","key":"10.1016\/j.jtct.2026.04.035_bib0007","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"25","key":"10.1016\/j.jtct.2026.04.035_bib0008","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"388","author":"Bolanos-Meade","year":"2023","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.jtct.2026.04.035_bib0009","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1182\/bloodadvances.2021005847","article-title":"Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial","volume":"6","author":"Broers","year":"2022","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.jtct.2026.04.035_bib0010","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1056\/NEJMoa2503189","article-title":"Graft-versus-host disease prophylaxis with cyclophosphamide and cyclosporin","volume":"393","author":"Curtis","year":"2025","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jtct.2026.04.035_bib0011","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/bmt.2016.225","article-title":"Patterns of infection and infection-related mortality in patients with steroid-refractory acute graft versus host disease","volume":"52","author":"Garcia-Cadenas","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2026.04.035_bib0012","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/s41409-024-02474-1","article-title":"Immunological reconstitution and infections after alloHCT - a comparison between post-transplantation cyclophosphamide, ATLG and non-ATLG based GvHD prophylaxis","volume":"60","author":"Meyer","year":"2025","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.jtct.2026.04.035_bib0013","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jaccao.2021.02.011","article-title":"Early cardiac toxicity associated with post-transplant cyclophosphamide in allogeneic stem cell transplantation","volume":"3","author":"Dulery","year":"2021","journal-title":"JACC CardioOncol"},{"issue":"12","key":"10.1016\/j.jtct.2026.04.035_bib0014","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining the intensity of conditioning regimens: working definitions","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jtct.2026.04.035_bib0015","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/s41409-024-02251-0","article-title":"Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMT","volume":"59","author":"Sureda","year":"2024","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.04.035_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2023.101128","article-title":"Classification, risk stratification and response assessment in myelodysplastic syndromes\/neoplasms (MDS): a state-of-the-art report on behalf of the International Consortium for MDS (icMDS)","volume":"62","author":"Stahl","year":"2023","journal-title":"Blood Rev"},{"issue":"11","key":"10.1016\/j.jtct.2026.04.035_bib0017","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1038\/s41409-018-0204-7","article-title":"EBMT-NIH-CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment","volume":"53","author":"Schoemans","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2026.04.035_bib0018","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","article-title":"International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD International Consortium","volume":"22","author":"Harris","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2026.04.035_bib0019","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2026.04.035_bib0020","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software 'EZR' for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.jtct.2026.04.035_bib0021","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/s41409-023-01931-7","article-title":"Outcome after allogeneic stem cell transplantation with haploidentical versus HLA-matched donors in patients with higher-risk MDS","volume":"58","author":"Michel","year":"2023","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1016\/j.jtct.2026.04.035_bib0022","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17071109","article-title":"Post-transplant cyclophosphamide-based prophylaxis and its impact on infectious complications and immune reconstitution according to donor type","volume":"17","author":"Merchan-Munoz","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"14","key":"10.1016\/j.jtct.2026.04.035_bib0023","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1182\/bloodadvances.2025015964","article-title":"Impact of posttransplant cyclophosphamide-based GVHD prophylaxis in patients 70 years and older: an update from BMT CTN 1703","volume":"9","author":"Abedin","year":"2025","journal-title":"Blood Adv"},{"issue":"18","key":"10.1016\/j.jtct.2026.04.035_bib0024","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1182\/blood.2024025131","article-title":"Clinical-genomic profiling of MDS to inform allo-HCT: recommendations from an international panel on behalf of the EBMT","volume":"145","author":"Gurnari","year":"2025","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jtct.2026.04.035_bib0025","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jtct.2022.11.014","article-title":"Hematopoietic cell transplantation in the management of myelodysplastic syndrome: an evidence-based review from the american society for transplantation and cellular therapy committee on practice guidelines","volume":"29","author":"DeFilipp","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"10.1016\/j.jtct.2026.04.035_bib0026","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1182\/blood.2023022273","article-title":"Does IPSS-R downstaging before transplantation improve the prognosis of patients with myelodysplastic neoplasms?","volume":"144","author":"Scheid","year":"2024","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.jtct.2026.04.035_bib0027","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/S1470-2045(18)30580-1","article-title":"Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial","volume":"19","author":"Platzbecker","year":"2018","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.jtct.2026.04.035_bib0028","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.3324\/haematol.2022.282570","article-title":"Azacitidine, lenalidomide and donor lymphocyte infusions for relapse of myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia after allogeneic transplant: the Azalena-Trial","volume":"108","author":"Schroeder","year":"2023","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.jtct.2026.04.035_bib0029","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1804714","article-title":"Mutation clearance after transplantation for myelodysplastic syndrome","volume":"379","author":"Duncavage","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jtct.2026.04.035_bib0030","first-page":"339","article-title":"Treatment of high-risk myelodysplastic syndromes","volume":"110","author":"Kroger","year":"2025","journal-title":"Haematologica"},{"issue":"19","key":"10.1016\/j.jtct.2026.04.035_bib0031","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1200\/JCO.2016.70.7349","article-title":"Dose-reduced versus standard conditioning followed by allogeneic stem-cell transplantation for patients with myelodysplastic syndrome: a prospective randomized phase III study of the EBMT (RICMAC trial)","volume":"35","author":"Kroger","year":"2017","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.jtct.2026.04.035_bib0032","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1200\/JCO.2016.70.7091","article-title":"Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes","volume":"35","author":"Scott","year":"2017","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.jtct.2026.04.035_bib0033","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/s41409-024-02241-2","article-title":"Fludarabine-treosulfan versus fludarabine-melphalan or busulfan-cyclophosphamide conditioning in older AML or MDS patients: a clinical trial to registry data comparison","volume":"59","author":"Beelen","year":"2024","journal-title":"Bone Marrow Transplant"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726003210?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726003210?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T12:36:24Z","timestamp":1785414984000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726003210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":33,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2666636726003210"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.04.035","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes of Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide Prophylaxis in Myelodysplastic Syndromes: A Multicenter Study Conducted on Behalf of GETH-TC","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.04.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}